
    
      The objectives of study are to 1) determine the incidence of adverse events and adverse drug
      reactions among patients receiving evolocumab for up to 2 years, and 2) identify and describe
      patient characteristics (e.g. demographics, medical history) associated with the safety and
      effectiveness of evolocumab therapy for the patients with Familial Hypercholesterolemia
      (Heterozygous or Homozygous) and Hypercholesterolemia in Japan
    
  